Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2019-04-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases
NCT03113344
Population Pharmacokinetics of Cephalosporins and Macrolides in Chinese Children With Community Acquired Pneumonia
NCT02775968
Xiyanping Injection Combined With Azithromycin VS Azithromycin for Children With pneumoniaProtozoal Pneumonia
NCT04296383
Key Specialized Monitoring of Clinical Safety of Pudilan Xiaoyan Oral Liquid in the Real World
NCT04031651
Population Pharmacokinetics of Meropenem and Linezolid in Children With Severe Infectious Diseases
NCT03643497
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Teicoplanin-PMMA
Therapeutic drug monitoring of teicoplanin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Teicoplanin was used for therapeutic purposes;
* Age:≤18 years;
* Clinician confirms and plans to diagnose the patient with gram-positive coccus infection;
* Patients with therapeutic concentration monitoring of teicoplanin.
Exclusion Criteria
* Teicoplanin was used for prophylactic purposes;
* Patients without therapeutic concentration monitoring of teicoplanin;
* Patients who die within 24 hours of the use of teicoplanin；
* The blood concentrations of the patient was not approved by the quality control center.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qianfoshan Hospital
OTHER
Shandong Provincial Hospital
OTHER_GOV
Affiliated Hospital of Qinghai University
OTHER
Jinan children's hospital
UNKNOWN
Yantai Yuhuangding Hospital
OTHER
Jinan Central Hospital
OTHER
Liaocheng People's Hospital
OTHER
Shandong Tumor Hospital
OTHER
Weifang People's Hospital
OTHER
Linyi People's Hospital
OTHER
Jining Medical University
OTHER
Weihai maternal and child health care hospital
UNKNOWN
The Second Hospital of Shandong University
OTHER
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Zhao
Head of department of clinical pharmacy and pharmacology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shandong Provincial Qianfoshan Hospital
Ji'nan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019_Teicoplanin_001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.